Tech Company Financing Transactions
C4 Therapeutics Funding Round
On 6/17/2020, C4 Therapeutics raised $170 million in Series B funding from Cobro Ventures, Perceptive Advisors and 3E Bioventures.
Transaction Overview
Company Name
Announced On
6/17/2020
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$170,000,000
Round
Series B
Investors
Cobro Ventures (Lead Investor) (Todd Kaloudis)
Perceptive Advisors (Lead Investor) (Adam Stone)
Proceeds Purpose
C4T will use the proceeds to advance multiple degrader drug candidates to human proof-of-concept and to expand the Company's capabilities.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
490 Arsenal Way 200
Watertown, MA 02472
USA
Watertown, MA 02472
USA
Phone
Website
Email Address
Not Recorded
Overview
C4 Therapeutics (Nasdaq: CCCC) is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Marc Cohen
Chief Financial Officer
William McKee
Chief Medical Officer
Adam Crystal
Chief Scientific Officer
Stew Fisher
Browse more venture capital transactions:
Prev: 6/17/2020: DeepSource venture capital transaction
Next: 6/17/2020: Streamlit venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs